

November 28th, 2023

SBI Pharmaceuticals Co., Ltd.
Scivita Medical Technology Co., Ltd.

SBI Pharma and Scivita Medical entered into exclusive distribution agreement of single use endoscopes in urology field in Japan

SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director & President: Yoshitaka Kitao; hereinafter “SBI Pharma”), a subsidiary company of SBI Holdings, Inc. which conducts research and development pharmaceuticals, etc., utilizing 5-aminolevulinic acid (*) and Scivita Medical Technology Co., Ltd. (Head office: Suzhou, People's Republic of China; General Manager: Dr. CHIN To; hereinafter “Scivita”), a medical device company that provides minimally invasive diagnosis and treatment solutions, and focuses on research, development and commercialization of medical endoscopes and related products, have officially signed an exclusive distributorship agreement for Scivita’s Single-Use Urology Videoscope, including single-use ureteroscope and disposable cystoscope in Japan.

SBI Pharma has developed “ALAGLIO Divided Granules 1.5g” and “ALAGLIO Oral 1.5g,” photodynamic diagnosis (PDD) agents indicated for visualization of non-muscle invasive bladder cancer during transurethral bladder tumor resection (TURBT), and the medical light source device “Aladuck 405,” and provide them to urology doctors in Japan.

Scivita has a comprehensive product lineup including reusable and single-use endoscopes, related equipment, and systems for various clinical departments, in China, Europe, America, and other countries.

Due to the risk of cross-contamination and the burden of maintenance and sterilization, demand for disposable, single-use endoscopes are increasing in the urology field. Through this partnership, SBI Pharma and Scivita plan to launch single-use endoscopes for urology before the end of 2023.

About Scivita Medical

Founded in 2016, Scivita Medical is a medical device company that provides minimally invasive diagnosis and treatment solutions, and focuses on the research, development and commercialization of medical endoscopes and related products. Scivita Medical takes

'Globalization' as its core strategy and has established R&D centers both in China and Japan. With solid in-house R&D capabilities, Scivita Medical has established a unique technology platform built upon five synergistic core technologies, and built a comprehensive portfolio of endoscope products and products candidates covering all types of endoscope procedures conducted by the various clinical departments, to address diverse medical needs. Adhering its value of 'Clinical Focus' 'Collaborative Innovation' 'People Oriented' 'Excellence & Efficiency', Scivita Medical will continuously upgrade its core technologies, improve market penetration with excellent products, and to be the preferred brand trusted by doctors and patients around the world.

For more information, please visit: scivitamedical.com/#/

(*) 5-aminolevulinic acid (5-ALA): An amino acid produced in mitochondria. It is an important substance that serves as a functional molecule related to energy production in the form of heme and cytochromes, and its productivity is known to decrease with age. 5-ALA is contained in food such as shochu lees, red wine and Asian ginseng. It is also known as a material forming chloroplasts in plants.

For further information, please contact:

SBI Pharmaceuticals Co., Ltd.: Tel: +81-3-6229-0095 E-mail: info_ala@sbigroup.co.jp

Scivita Medical Technology Co., Ltd.: Tel: +86-512-8717 4749

Email

Sales Contact : info@scivitamedical.com

Media Contact : TingWang@scivitamedical.com